Orgenesis Enters Asset Purchase Agreement With Broaden Bioscience For CAR-T Processing Assets; Will Pay Up To $11M Based On Third Party Valuation; Payment Exceeding $10.77M Debt May Be Made In Shares Or A Note With 24-Month Amortization
Orgenesis Enters Asset Purchase Agreement With Broaden Bioscience For CAR-T Processing Assets; Will Pay Up To $11M Based On Third Party Valuation; Payment Exceeding $10.77M Debt May Be Made In Shares Or A Note With 24-Month Amortization
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.